The cryo-thermal therapy-induced IL-6-rich acute pro-inflammatory response promoted DCs phenotypic maturation as the prerequisite to CD4⁺ T cell differentiation

References

• Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22:275–81.
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, et al. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514–22.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–3.
   PubMed Web of Science ®Google Scholar
• Lee CT, Mace T, Repasky EA. (2010). Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 26:232–46.
   PubMed Web of Science ®Google Scholar
• McCarter MD, Baumgartner J, Escobar GA, et al. (2007). Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 14:2854–60.
   PubMed Web of Science ®Google Scholar
• Yu X, Guo C, Yi H, et al. (2013). A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Cancer Res 73:2093–103.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Singh R, Sabharwal L, et al. (2014). Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74:8–14.
   PubMed Web of Science ®Google Scholar
• Bunt SK, Clements VK, Hanson EM, et al. (2009). Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85:996–1004.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420:860–7.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. (2015). Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 36:1085–93.
   PubMed Web of Science ®Google Scholar
• Huang L, Baban B, Johnson BA, Mellor AL. (2010). Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 29:133–55.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Ostrand-Rosenberg S. (2005). Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol Res 174:636–45.
   Google Scholar
• Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507–13.
   PubMed Web of Science ®Google Scholar
• Milani V, Noessner E, Ghose S, et al. (2002). Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia 18:563–75.
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946–52.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Coussens LM. (2007). Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:1.
   Web of Science ®Google Scholar
• Dmitrieva OS, Shilovskiy IP, Khaitov MR, Grivennikov SI. (2016). Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochemistry (Moscow) 81:80–90.
   PubMed Web of Science ®Google Scholar
• Fisher DT, Appenheimer MM, Evans SS. (2014). The two faces of IL-6 in the tumor microenvironment. Semin Immunol 26:38–47.
   PubMed Web of Science ®Google Scholar
• Gabay C. (2006). Interleukin-6 and chronic inflammation. Arthritis Res Ther 8:1.
   Web of Science ®Google Scholar
• Angell Helen GJ. (2013). From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25:261–7.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang A, Xu Y, Xu LX. (2005). Study of non-uniform nanoparticle liposome extravasation in tumour. Int J Hyperthermia 21:259–70.
   PubMed Web of Science ®Google Scholar
• Dong J, Liu P, Xu LX. (2009). Immunologic response induced by synergistic effect of alternating cooling and heating of breast cancer. Int J Hyperthermia 25:25–33.
   PubMed Web of Science ®Google Scholar
• Shen Y, Liu P, Z A, Xu LX. (2008). Study on tumor microvasculature damage induced by alternate cooling and heating. Ann Biomed Eng 36:1409–19.
   PubMed Web of Science ®Google Scholar
• Bai JF, L P, Xu∗ LX. (2014). Recent advances in thermal treatment techniques and thermally induced immune responses against cancer. Ieee 61:1497–505.
   Google Scholar
• Zhu J, Zhang Y, Zhang A, et al. (2016). Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. Sci Rep 6:27136.
   PubMed Web of Science ®Google Scholar
• Xue TLP, Zhou Y, Liu K, et al. (2016). Interleukin-6 induced “acute” phenotypic microenvironment promotes Th1 anti-tumor immunity in cryo-thermal therapy revealed by shotgun and parallel reaction monitoring proteomics. Theranostics 6:773–94.
   PubMed Web of Science ®Google Scholar
• Lisa MC, Zitvogel L, Karolina Palucka A. (2013). Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–91.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–7.
   PubMed Web of Science ®Google Scholar
• Fontes JA, Rose NR, Čiháková D. (2015). Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Cytokine 74:62–8.
   PubMed Web of Science ®Google Scholar
• Bickels J, Kollender Y, Merinsky O, Meller I. (2002). Coley's toxin: Historical perspective. Isr Med Assoc J 4:471–2.
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. (2006). Dendritic cells in a mature age. Nat Rev Immunol 6:476–83.
   PubMed Web of Science ®Google Scholar
• Moreau A, Hill M, Thebault P, et al. (2009). Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. Faseb j23:3070–7.
   PubMed Web of Science ®Google Scholar
• Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. (2015). Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194:2985–91.
   PubMed Web of Science ®Google Scholar
• Krempski J, Karyampudi L, Behrens MD, et al. (2011). Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186:6905–13.
   PubMed Web of Science ®Google Scholar
• Bleul CBC, Fuhlbrigge RC, Casasnovas JM, et al. (1996). A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med 184:110l–9.
   Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–81.
   PubMed Web of Science ®Google Scholar
• Mukhopadhaya A, Mendecki J, Dong X, et al. (2007). Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res 67:7798–806.
   PubMed Web of Science ®Google Scholar
• Caserta S, Borger JG, Zamoyska R. (2012). Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens. Crit Rev Immunol 32:97–126.
   PubMed Web of Science ®Google Scholar
• Pardoll DM, Topalian SL. (1998). The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588–94.
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, et al. (1998). The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–68.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cantor H. (2014). CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2:91–8.
   PubMed Web of Science ®Google Scholar
• Ankathatti Munegowda M, Deng Y, Mulligan SJ, Xiang J. (2011). Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 60:1473–84.
   PubMed Web of Science ®Google Scholar
• Zhou S, Dong X, Zhang C, et al. (2015). MicroRNAs are implicated in the suppression of CD4 + CD25− conventional T cell proliferation by CD4 + CD25+ regulatory T cells. Mol Immunol 63:464–72.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. (2012). T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72:2162–71.
   PubMed Web of Science ®Google Scholar
• Santonja C, Soto C, Manso R, et al. (2016). Primary cutaneous follicular helper T-cell lymphoma. J Cutan Pathol 43:164–70.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Daenthanasanmak A, Meek M, et al. (2016). Hybrid Th1/17 cells possess unique immuno-metabolic phenotype and surpiror anti-tumor activity. J Immunol 196:214.18–.18.
   Google Scholar
• Li J, Yue L, Wang H, et al. (2016). Th17 cells exhibit antitumor effects in mds possibly through augmenting functions of CD8+ T cells. J Immunol Res 2016:9404705.
   PubMedGoogle Scholar
• Thery C, Duban L, Segura E, et al. (2002). Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3:1156–62.
   PubMed Web of Science ®Google Scholar
• Ito T, Wang YH, Duramad O, et al. (2005). TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202:1213–23.
   PubMed Web of Science ®Google Scholar
• Beury DW, Parker KH, Nyandjo M, et al. (2014). Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol 96:1109–18.
   PubMed Web of Science ®Google Scholar
• Caetano MS, Zhang H, Cumpian AM, et al. (2016). IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer. Cancer Res 76:3189–99.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–13.
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, et al. (2012). Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 72:2473–80.
   PubMed Web of Science ®Google Scholar
• Shiao SL, Ganesan AP, Rugo HS, Coussens LM. (2011). Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 25:2559–72.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck J-P, et al. (2003). Plasmacytoid dendritic cells induce plasma cell differentiation through type i interferon and interleukin 6. Immunity 19:225–34.
   PubMed Web of Science ®Google Scholar
• Karczmarczyk A, Karp M, Giannopoulos K. (2014). The role of Th17 cells in tumor immunity. Acta Haematol Pol 45:155–60.
   Google Scholar
• Mikucki ME, Fisher DT, Ku AW, et al. (2013). Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. Int J Hyperthermia 29:464–73.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. (2013). Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38–48.
   PubMed Web of Science ®Google Scholar
• Demoulin S, Herfs M, Delvenne P, Hubert P. (2013). Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 93:343–52.
   PubMed Web of Science ®Google Scholar
• Li DY, Gu C, Min J, et al. (2012). Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 4:131–4.
   PubMed Web of Science ®Google Scholar
• Sheng K-CP, Geoff A, Wright MD, Apostolopoulos V. (2005). Dendritic cells: activation and maturation: applications for cancer immunotherapy. Curr Med Chem 12:18.
   Web of Science ®Google Scholar
• Zheng W, Chen J, Liu C, et al. (2016). Immature CD11c + myeloid dendritic cells with inflammatory and regulatory cytokine profile in human seminoma. Int J Clin Exp Pathol 9:2803–19.
   Web of Science ®Google Scholar
• Ma Y, Shurin GV, Peiyuan Z, Shurin MR. (2013). Dendritic cells in the cancer microenvironment. J Cancer 4:36–44.
   PubMed Web of Science ®Google Scholar
• Hope JC, Cumberbatch M, Fielding I, et al. (1995). Identification of dendritic cells as a major source of interleukin-6 in draining lymph nodes following skin sensitization of mice. Immunology 86:441–7.
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Ocadlikova D, Ciciarello M, et al. (2014). The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol 192:1231–40.
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, et al. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–70.
   PubMed Web of Science ®Google Scholar
• Grohmann U, Fallarino F, Bianchi R, et al. (2001). IL-6 inhibits the tolerogenic function of CD8 alpha + dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol 167:708–14.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Takemoto N, Wherry EJ, et al. (2005). Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6:1236–44.
   PubMed Web of Science ®Google Scholar
• Sullivan BM, Juedes A, Szabo SJ, et al. (2003). Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci USA 100:15818–23.
   PubMed Web of Science ®Google Scholar
• Wu W, Dietze KK, Gibbert K, et al. (2015). TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection. Sci Rep 5:10501.
   PubMed Web of Science ®Google Scholar
• Geng D, Zheng L, Srivastava R, et al. (2010). When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 116:3494–504.
   PubMed Web of Science ®Google Scholar
• Longhi MP, Wright K, Lauder SN, et al. (2008). Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog 4:e1000006
   PubMed Web of Science ®Google Scholar